Evolution of Therapy in HCV
|
|
- Maria Lucas
- 6 years ago
- Views:
Transcription
1 Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV (%) SVR IFN IFN 6m 12m IFN/ 6m 25 IFN/ 12m PEG/ 12m PEG/R/PI 6-12m 1
2 New Therapies for Genotype 1 IFN IFN Free Naïve Treatment experienced Cirrhosis Classes of New Therapies Liver International pages 93-14, 3 JAN 13 DOI: /liv
3 DAAs in Late-Stage Clinical Development for Chronic HCV Infection NS3/4A Protease Inhibitors Nucleotide NS5B Polymerase Inhibitors Non-Nucleoside NS5B Polymerase Inhibitors NS5A Replication Complex Inhibitors Approved Boceprevir Telaprevir Simeprevir Sofosbuvir Phase 3 ABT-45* Asunaprevir* Faldaprevir ABT-333 BI 7127 Daclatasvir* ABT-267* GS-5885* Phase 2 Danoprevir GS-9256 GS-9451 MK-5172 Sovaprevir Filibuvir Mericitabine ABT-72 BMS Setrobuvir Tegobuvir VX-222 IDX719 MK8742 NEW INTERFERONS 3
4 PEGLAMBDA INTERFERON REDUCED SIDE EFFECTS Lambda Alpha Headache Arthralgia 6 33 Myalgia 6 Fever 8 33 Insomnia Chills 4 21 Rash Itching Irritability AJ Muir et al Gastroenterol 13: (in press) PEGLAMBDA INTERFERON REDUCED SIDE EFFECTS AJ Muir et al Gastroenterol 13: (in press) 4
5 COMBINING NEW APPROVED THERAPIES FOR GENOTYPE 1 COSMOS: Genotype 1 Week N=14 Arm 1 SMV + SOF + Post-treatment follow-up N=24 Arm 2 SMV + SOF Post-treatment follow-up N=14 Arm 3 SMV + SOF + Post-treatment follow-up N=27 Arm 4 SMV + SOF Post-treatment follow-up Enrolment ratio 2:1:2:1 Cohort 1: Prior null responders (METAVIR F-F2) Final SVR12 for all arms Cohort 2: Treatment-naïve and prior null responders (METAVIR F3-F4) Interim SVR4 for Arms 3 and 4 Jacobson et al AASLD 13 5
6 Patients (%) 24 week treatment 1/ / /24 1 SMV/SOF SMV/SOF/ 24 wks 24 wks 12 week treatment 7.8 1/ / /14 26/27 SMV/ SMV/SOF SOF SMV/ SMV/SOF/ SOF/ 12 wks 12 wks SVR12 (SMV/SOF) SVR12 (SMV/SOF/) Non-virologic failure Relapse Jacobson et al AASLD week treatment Patients (%) 1/ /14 26/27 7/7 12/12 7/7 14/15 Total Naives Nulls 9 naïve and 9 null responders METAVIR F4 patients Only relapser was a F4 prior null responder 1/15 SVR4 (SMV/SOF) SVR4 (SMV/SOF/) Relapse Jacobson et al AASLD 13 6
7 NEW THERAPIES FOR GENOTYPE 1: IFN FREE SVR12 Rates (ITT) for 8- and 12-Week Arms Perce entage of patients (ITT) achieving SVR 12 N= N=41 N=79 N=79 N=79 N=45 N=45 8 weeks 12 weeks 12 weeks ABT-45 ABT-267 ABT-333 ABT-45 ABT-333 ABT-45 ABT-267 ABT-45 ABT-267 ABT-333 Treatment-naϊve Patients ABT-45 ABT-267 ABT-333 ABT-45 ABT-267 ABT-45 ABT-267 ABT-333 Null Responders Kowdley K, et al. 63rd AASLD; Boston, MA; November 9-13, 12. Abst. LB-1. 7
8 AVIATOR: SVR12 Rates With ABT-45/RTV, ABT-267, ABT-333, and No drug-related SAEs reported SV VR12 (%) Treatment-Naive Patients 98 Observed data (above bar) ITT (within bar) n = a 1b 1a 1b 1a 1b 1a 1b 1a 1b ABT-45 ABT-267 ABT-333 ABT-45 ABT-333 ABT-45 ABT wks 12 wks ABT-45 ABT-267 ABT-333 ABT-45 ABT-267 ABT-333 Kowdley KV, et al. AASLD 12. Abstract LB-1. Aviator: Null response results Kowdley KV, et al. AASLD 12. Abstract LB-1. 8
9 Sapphire 1 Trial: ABT-45/r, ABT-267, ABT-333, Naïve, Genotype 1a and 1b Non-cirrhotic 631 patients ABT 45/r, ABT-267 co-formulated into 1 pill ABT-333, dosed twice daily AE s fatigue, headache, nausea Enanta/ABBVIE Press release 11/18/13 Sapphire 1 Trial: SVR d/c rate in all arms 1.7% relapse rate All n=473 G 1a n=322 G 1b n=151 Placebo n=218 Enanta/Abbvie Press Release 11/18/13 9
10 Direct-Acting Antiviral Agents Daclatasvir (DCV) NS5A replication complex inhibitor with potent, pan-genotypic activity in vitro Studied in over 55 patients Asunaprevir (ASV) NS3 protease inhibitor active against genotypes (GT) 1, 4, 5, and 6 in vitro Studied in over patients BMS Non-nucleoside, NS5B polymerase inhibitor active against GT 1, 3, 4, 5, and 6 in vitro Studied in over 5 patients Everson et al AASLD 13 Randomized, Phase 2b Open-Label Study (AI443-14) Primary endpoint: SVR 12 N = N = 86 DCV 3 mg BID + ASV mg BID + BMS mg BID DCV 3 mg BID + ASV mg BID + BMS mg BID 12-week follow-up Additional follow-up to SVR 48 Week Patients: treatment-naive, stratified by GT 1a/1b and presence of biopsy- confirmed cirrhosis i (82% GT1a and 9% cirrhotics). Primary end point: HCV RNA < LLOQ 12 weeks post-treatment (SVR 12 ) Observed analysis: breakthrough, relapse, addition of pegifnα/ = failure Modified intent-to-treat analysis: missing, breakthrough, relapse or addition of pegifnα/ = failure Everson et al AASLD 13 1
11 Efficacy Through SVR 12 (Observed) Res sponse, % of patients 78/ 81/86 73/79 77/84 71/77 77/84 DCV + ASV mg DCV + ASV mg End of Treatment SVR 4 SVR 12 Everson et al AASLD 13 Event, n (%) Safety Outcomes DCV + ASV + DCV + ASV mg mg N = N = 86 Total N = 166 Serious AEs 1(13) (1.3) 2(23) (2.3) 3(16) (1.6) AEs leading to discontinuation 1 (1.3) 1 (1.2) 2 (1.1) Grade 3/4 AEs 1 (1.2) 1 (.5) Most frequent on-treatment AEs ( 1%) Headache 17 (21.3) 24 (27.9) 41 (24.7) Diarrhea 12 (15.) 13 (15.1) 25 (15.1) Fatigue 12 (15.) 7 (8.1) 19 (11.4) Nausea 1 (12.5) 7 (8.1) 17 (1.2) Grade 3/4 lab abnormalities Aspartate aminotransferase (AST) 1 (1.3) 1 (.5) Glucose, fasting serum (high) 1 (1.3) 1 (1.2) 2 (1.2) Phosphorus, inorganic 1 (1.2) 1 (.5) Bilirubin, total 1 (1.2) 1 (.5) Everson et al AASLD 13 11
12 NEW THERAPIES FOR GENOTYPE 1: COFORMULATED AGENTS Direct Acting Antiviral Agents Sofosbuvir/Ledipasvir FDC Once daily, oral fixed-dose (/9 mg) combination tablet No food effect > patients treated SOF Nucleotide Polymerase inhibitor LDV NS5A inhibitor GS-9669 HCV NS5B non-nucleoside inhibitor, binding at thumb site II of the polymerase Potent antiviral activity with QD dosing Nanomolar potency against GT 1a and 1b Gane et al AASLD 13 12
13 Study Design Wk Wk 6 Wk 12 F4 omized Rando SOF/LDV FDC (n=1) SOF/LDV FDC + (n=1) GT 1 Experienced F3/F4 Randomized SOF/LDV FDC + (n=25) SOF/LDV FDC + GS-9669 (n=25) SVR12 GT 1 Naïve F/F1/F2 SOF/LDV FDC + (n=25) Primary endpoint: SVR12 (HCV RNA <LLOQ) Patients enrolled in ELECTRON or ELECTRON 2 (GT1, F3/F4) All groups were open label Gane et al AASLD 13 SVR 12 (%) /1 9/9 25/25* 26/26* SOF/LDV SOF/LDV + SOF/LDV + SOF/LDV + GS9669 Duration (wk) F4 only F3/F4 *From ELECTRON 2 Gane et al AASLD 13 13
14 SVR 12 (%) /25 21/21 17/25 SOF + LDV + * SOF/LDV + SOF/LDV + Duration (wk) *Gane et al. EASL 13. Lawitz et al AASLD 13 (LONESTAR) Conclusions In treatment-experienced patients with advanced fibrosis/cirrhosis, either or GS may enhance the efficacy of SOF/LDV given for 12 weeks The optimal duration of SOF/LDV in treatmentnaïve GT 1 patients (even with the addition of ) is more than 6 weeks Regimens of SOF/LDV alone, or with or with GS-9669, were safe and well tolerated Gane et al AASLD 13 14
15 n=25 MK-5172 ( mg) + MK-8742 ( mg) + ; G1a & G1b Follow-up n=27 MK-5172 ( mg) + MK-8742 (5 mg) + ; G1a & G1b Follow-up n=13 MK-5172 ( mg) + MK-8742 (5 mg); G1b Follow-up D1 TW4 TW12 SVR4 SVR8 SVR12 SVR24 Lawitz et al AASLD 13 % HCV-RNA <25 IU/mL TW4 TW12 SVR4 SVR MK-5172 ( mg) + MK ( mg) + (n=25) MK-5172 ( mg) + MK (5 mg) + (n=27) MK-5172 ( mg) + MK (5 mg) (n=13) Lawitz et al AASLD 13 Treatment Follow-up 15
16 Number of patients (%) MK-5172 Common MK-5172 MK-5172 mg mg Adverse mg + MK MK Event mg + MK All arms mg mg + N=65 + n=25 n=28 n=12 Fatigue 8 (32) 5 (18) 4 (33) 17 (26) Headache 4 (16) 5 (18) 5 (42) 14 (22) Nausea 3 (12) 7 (25) 2 (17) 12 (18) Diarrhea 3 (12) 4 (14) 1(8) 8 (12) Dizziness 4 (16) 2 (7) 1 (8) 7 (11) Rash 1 (4) 5 (18) 1 (8) 7 (11) * Incidence 1% in all arms Lawitz et al AASLD 13 Study Design and Methods Treatment Period PostTreatment Period Cohort 1 (n=12) mg BID DBV + 1 mg QD FDV* + mg QD Cohort 2 (n=12) mg BID DBV + 1 mg QD FDV* + mg QD Cohort 3 (n=12) mg BID DBV + 1 mg QD FDV* + mg QD 668 (no ) Day Week 12 Week 16 SVR4 Week 24 SVR12 Week 36 SVR24 *FDV loading dose (2 mg) on Day 1 Lalezari et al AASLD 13 16
17 <LLOQ/<LLOD (%) 1 Cohort Cohort Cohort 3 (- All Time 1 n 2 n free) n Cohorts n Week 2 92/ / / /42 36 Week 4 92/75 12 / 12 / /81 36 Week 6 / 11 2 /92 12 / 1 /97 33 Week 8 / 11 2 / 11 / 4 / 26 Week 12 / 9 2 / 8 N/A 3 / 17 SVR4 / 7 2 / 6 N/A 3 / 13 Overall, 97% of patients across all three cohorts achieved HCV RNA <LLOQ (81% <LLOD) at week 4, regardless of use NEW THERAPIES FOR GENOTYPE 1: IFN AND FREE 17
18 N BL HCV Genotype/Regimen Treatment Experience Week 12 Week 24 Substudy 1: Patients Without Cirrhosis Substudy 2: Patients With Compensated Cirrhosis Group 1 GT4 ABT-45/r + ABT-267 Treatment-naïve Group 2 GT1b ABT-45/r + ABT-267 Treatment-naïve Group 3 GT1b ABT-45/r + ABT-267 Group 4 Null Responders Group 5 GT4 ABT-45/r + ABT rbv Treatment-naïve Group 6 GT4 ABT-45/r + ABT-267 Partial/Null Responders & Relapsers Group 7 GT4 ABT-45/r + ABT rbv Group 8 Partial/Null Responders & Relapsers GT1b ABT-45/r + ABT-267 Treatment-naïve GT1b ABT-45/r + ABT-267 Partial/Null Responders & Relapsers ABT-45/r 15/ mg QD; ABT mg QD; weight based, mg or 1 mg daily divided BID. Patients followed through 48 weeks post-treatment Lawitz et al AASLD 13 ercentage of Patients P /42 41/42 41/42 /42 Week 4 Week 12 SVR SVR EOTR 4 12 Lawitz et al AASLD 13 18
19 ercentage of Patients P Lawitz et al AASLD / 39/ 37/ 36/ Week 4 Week 12 SVR SVR EOTR 4 12 Event, n (%) GT1b-infected Treatment-naïve Patients (N=42) GT1b-infected Prior Null Responders (N=) Headache 14 (3.3) 1 (25.) Nausea 8 (19.) Dry Skin 7 (16.7) Fatigue 6 (14.3) Pruritus 6 (14.3) Diarrhea 6 (14.3) Lawitz et al 13 19
20 HCV RNA < LLOQ, n (%) Ineligible naïve/intolerant (IN/I) Patients n = 135 a Nonresponder (NR) Patients n = 87 b Total N = 222 RVR, Week (84.4) 53 (.9) 167 (75.2) cevr, Week (92.6) 77 (88.5) 2 (91.) SVR (93.3) 71 (81.6) 197 (88.7) SVR 12 1 (88.9) 7 (.5) 19 (85.6) SVR (87.4) 7 (.5) 188 (84.7) a Ineligible naïve: n=; Intolerant: n=35 b Null responders: n=48; Partial responders: n=36; Undetermined: n=3 Abstract #211 Chayama et al AASLD 13 TREATMENT OF PI EXPERIENCED: IFN FREE THERAPIES
21 Once Daily Sofosbuvir/Ledipasvir Fixed Dose Combination with or without Ribavirin with HCV Genotype 1, Including Patients with Cirrhosis: the LONESTAR trial Wk Wk 8 Wk 12 Wk Wk 24 COHORT 1 (n=) Treatment Naïve (No cirrhosis) 1:1:1 Randomized SOF/LDV SOF/LDV + SOF/LDV SVR12 SVR12 SVR12 COHORT 2 (n=) PI Failures (5% cirrhosis) Randomized 1:1 SOF/LDV SOF/LDV + SVR12 SVR12 Single center study of GT 1 patients Broad inclusion criteria No upper limit to age or BMI Platelets 5,/mm 3 Lawitz et al AASLD 13 Results: Demographics of Patients Who Previously Failed PI Therapy PI Failures n= Prior treatment with boceprevir 22/ (55) Prior treatment with telaprevir 18/ (45) Cirrhosis, n (%) 22/ (55) Mean platelet count, x 1 3 /µl 17 Mean albumin, g/dl 3.8 All patients were required to have experienced virologic failure Patients who stopped prior therapy due to an AE were excluded Lawitz et al AASLD 13 21
22 Lonestar Results Patients (%) Duration (week) 19/ 21/21 18/19 18/19 21/ Lawitz et al AASLD 13 Treatment Naïve (No Cirrhosis) PI Failures (5% Cirrhosis) Daclatasvir + Sofosbuvir ± in GT 1 Pts With Prior Tx Failure on TVR or BOC Pts with GT 1 HCV and virologic failure on previous TVR- or BOC-based regimen (N = 41) Daclatasvir mg QD + Sofosbuvir mg QD (n = 21) Daclatasvir mg QD + Sofosbuvir mg QD + -1 mg/day (n = ) Wk 24 SVR4, % SVR12, % 95 45% to 48% had TVR/BOC resistance mutations, median 2.4 yrs since previous therapy No difference in response by absence/presence of resistance mutations Both regimens well tolerated; 1 serious AE; no discontinuations due to AEs Sulkowski MS, et al. EASL 13. Abstract
23 Evolution of Therapy in HCV Genotype ? SVR (%) IFN IFN IFN/ IFN/ 6m 12m 6m 12m PEG/ 12m PEG/R/PI 6-12m All Oral DAA weeks 23
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationBristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
More informationEASL and The Future of HCV Treatment
EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationThe Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago
The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationHighlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
More informationNS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationI nuovi farmaci per HCV: frequenza della patologia, evidenze di efficacia e sicurezza, strategie di gestione. la pratica clinica
I nuovi farmaci per HCV: frequenza della patologia, evidenze di efficacia e sicurezza, strategie di gestione La revisione ii delle dll evidenze e indicazioni i iper la pratica clinica Marco Marzioni Segretario
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Goals for Hepatitis C Therapy Compared to PegIFN/RBV, new products should offer: Improved efficacy Efficacy in all patient types including
More informationHepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Hepatitis C: Aplicaciones Clínicas de la Resistencia Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña DAA agents approved or in more advanced stages of clinical
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationStrategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany
Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer Hannover Medical School Hannover, Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Biolex,
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationThe Liver Meeting 2013: The 64th Annual Meeting of the AASLD Washington, DC, November 1 5, 2013 Presentation LB-1
Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection Everson GT,
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationMassimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda
Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda Innovative strategies in viral hepatitis : Hepatitis C: Interferon and/or Ribavirin free regimens 10th International Workshop on
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationNovember 2013 AASLD Investor Event 4 November
November 2013 AASLD Investor Event 4 November Maris Hartmanis, President and CEO Charlotte Edenius, EVP Development Bertil Samuelsson, CSA Rein Piir, EVP Corporate Affairs & IR Corporate presentation,
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationCase 2: A 71-year-old man with cirrhosis
Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years
More informationEd Gane NZ Liver Transplant Unit Auckland City Hospital
Clinical Management of Hepatitis C Patients Treat Now or Wait Ed Gane NZ Liver Transplant Unit Auckland City Hospital SVR24 rates with PEG/RBV by HCV genotype Data from the real-world PROPHESYS cohort
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationVIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
More informationNew Treatments for Chronic Hepatitis C. Rafael Esteban Hospital Valle Hebron. Barcelona Spain
New Treatments for Chronic Hepatitis C Rafael Esteban Hospital Valle Hebron. Barcelona Spain The present: a complex treatment with a better SVR Genotype 1 Genotypes 2 and 3 Triple therapy Boceprevir (BOC)
More informationInterferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist
Interferon Side Effects and The Future of Interferon Sparing Regimens Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL FEBRUARY 15,
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationCan a One-Size-Fits-All Approach Be Applied to All Treatment-Naïve GT1 HCV Patients?
Can a One-Size-Fits-All Approach Be Applied to All Treatment-Naïve GT1 HCV Patients? Ira M. Jacobson, MD Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationPegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University
More informationHepatitis C: New Therapies in
Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and
More informationThe Egyptian Plan to Cure HCV
The Egyptian Plan to Cure HCV Gamal Esmat Professor of Endemic Medicine & Hepatology Vice President of Cairo University for Graduate Studies and Research Disclosure Advisory Committee Board Member : MSD,
More informationHCV Treatment: Why to Wait
HCV Treatment: Why to Wait Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationHCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD
HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More information9/21/2014. Sarah Naidoo, PharmD, BCPS September 26, 2014
Sarah Naidoo, PharmD, BCPS September 26, 2014 Be able to discuss changes in hepatitis C treatment Be able to provide recommendations to providers regarding hepatitis C treatment Be able to provide patient
More informationO. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki
O. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki Disclosures Advisory Board: Abbvie Pharmaceuticals Speaker: Gilead Sciences, Bristol-Myers Squibb Research
More informationResistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic,
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Robert S. Brown, Jr., MD, MPH Frank Cardile Professor of Medicine Chief,
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More information